Total 80 healthy male or female middle aged or older subjects were assigned in 1:1 ratio to treatment with the test product, AbinoNutra™️ NMN supplement or Placebo in this Part 1 of double-blind, randomized, placebo-controlled study. 10 Healthy male or female middle aged or older subjects were assigned to the treatment with the test product AbinoNutra™️ NMN supplement with maximum dose (900 mg) in Part II. All 90 enrolled subjects were instructed to take two to six capsules (dependent on the arms that the subject fall into) of either AbinoNutra™️ NMN or Placebo once a day after breakfast for 60 days daily. Subjects were required to use diaries to document the date and time of study treatments including any missed doses and the occurrence of any adverse events.

The efficacy in terms of anti-aging effect in part I of the study was assessed primarily with the NAD+NADH concentration in blood, SF-36 questionnaire scoring, 6 Minute Walking Endurance test. HOMA and Biological age by aging.ai 3.0 calculator were explored too to assess AbinoNutra™️ NMN’s anti-aging effect.

There was a noteworthy rise in the SF 36 score seen in the AbinoNutra™️ NMN group which meant that the well-being of the subjects was increased by consuming AbinoNutra™️ NMN for 60 days.

There was a statistically significant difference between the 300 mg AbinoNutra™️ NMN supplement arm as compared to Placebo in Visit 4 for biological age values. Similar results were observed for the 600 mg and the 900 mg arms.

The analysis showed that there was no noteworthy change in HOMA score in the AbinoNutra™️ NMN group although there was a noteworthy rise in the placebo group by the end of study from the baseline. We can correlate these results with anti-aging effect of AbinoNutra™️ NMN as in the absence of AbinoNutra™️ NMN the parameter (HOMA IR Index) worsened. Also, the study population consisted of healthy volunteers and not diabetics or pre-diabetic population, where HOMA IR Index results could have been different.

In Part II, Telomere length was quantified for each subject and comparison from baseline to end of study was done for each subject individually.

The telomere length was seen to be increased for 3 subjects at 900 mg dose. In other 4 subjects the reduction in telomere length was not much from the baseline value at the start of the trial. Considering the short duration of treatment of 60 days, the results seem promising for the potential of AbinoNutra™️ NMN in its anti-ageing effect assessed by telomere length quantification.

For safety analysis, after the unblinding, during analysis, it was revealed that there were only 4 cases of AEs reported in AbinoNutra™️ NMN 300 mg arm, which were determined to be not related to 300 mg AbinoNutra™️ NMN by investigators. There were no AEs reported in 600 mg and 900 mg AbinoNutra™️ NMN arms in Part I, as well as in subjects included part II of the study, on 900 mg AbinoNutra™️ NMN dose.